Evaluation of Maternal Serum ELABELA Levels in Pregnancies Diagnosed With Abortus Imminens Between 8 and 14 Weeks of Gestation
Journal of Obstetrics and Gynaecology Research, cilt.52, sa.8, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 8
- Basım Tarihi: 2026
- Doi Numarası: 10.1111/jog.70450
- Dergi Adı: Journal of Obstetrics and Gynaecology Research
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Sociology Source Ultimate (EBSCO)
- Anahtar Kelimeler: abortus imminens, biomarker, early pregnancy, ELABELA, placental dysfunction
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Abortus imminens is a common condition in early pregnancy characterized by vaginal bleeding with a closed cervix and viable intrauterine pregnancy. Current biochemical markers have limited accuracy in predicting pregnancy outcomes. ELABELA (also known as Apela or Toddler), a peptide involved in angiogenesis and placental development, may serve as a potential biomarker in early pregnancy complications. This study aimed to evaluate maternal serum ELABELA levels in pregnancies diagnosed with abortus imminens. Methods: This prospective cross-sectional study included 45 pregnant women diagnosed with abortus imminens between 8 and 14 weeks of gestation and 45 healthy controls. Maternal serum ELABELA levels were measured using enzyme-linked immunosorbent assay (ELISA). All serum samples were analyzed simultaneously in a single analytical batch to minimize interassay variability. Statistical analyses included group comparisons, receiver operating characteristic (ROC) curve analysis, and binary logistic regression. Results: There were no significant differences between groups in terms of age, body mass index (BMI), gestational age at sampling, gravidity, or parity (p > 0.05). ELABELA levels were significantly lower in the abortus imminens group compared with controls (median: 649.82 vs. 859.60 pg/mL; p = 0.021). ROC analysis demonstrated modest discriminative ability (area under the curve [AUC] = 0.641; 95% confidence interval [CI]: 0.520–0.751), with an optimal cut-off value of 712.0 pg/mL (sensitivity 60.0%, specificity 68.9%). Logistic regression analysis showed no independent predictive value for ELABELA. Conclusion: Maternal serum ELABELA levels are significantly reduced in pregnancies with abortus imminens, suggesting a potential role in early placental dysfunction. Although ELABELA alone may not be a strong independent predictor, it may serve as a complementary biomarker in the evaluation of abortus imminens. Further large-scale prospective studies are needed to confirm these findings.